Results to be presented at the AASLD congress 2018, 9-13 November In a biopsy-confirmed fibrotic ob/ob NASH mouse model, icosabutate reduced hepatic fibrosis in association with a 45% decrease in myofibroblast content in pre- versus post-treatment liver biopsies In a...
Late breaker EASL Icosabutate, a structurally engineered fatty acid, displays optimised phamacokinetics for targeting both metabolic and inflammatory pathways in the liver, both with key relevance for NASH Pre-clinical data show broad and powerful pharmacodynamic...
Lead drug icosabutate, in-licensed from Pronova BioPharma AS Phase IIb-ready at the end of 2018 Naarden, The Netherlands, 12 December 2017 – NorthSea Therapeutics B.V. (‘NST’), a newly established Dutch biotech company, announced today the completion of a €25m Series...
